Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Lia Gore and Cindy O'Bryant.

 
Connection Strength
 
 
 
0.597
 
  1. Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2012 Oct; 30(5):1942-9.
    View in: PubMed
    Score: 0.100
  2. Lam ET, O'Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt SG, Gore L. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther. 2008 Dec; 7(12):3685-94.
    View in: PubMed
    Score: 0.082
  3. Lieu C, Chow L, Pierson AS, Eckhardt SG, O'Bryant CL, Morrow M, Tran ZV, Wright JJ, Gore L. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2009 Feb; 27(1):53-62.
    View in: PubMed
    Score: 0.080
  4. Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, Eckhardt SG. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008 Jul 15; 14(14):4517-25.
    View in: PubMed
    Score: 0.080
  5. O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol. 2009 Feb; 63(3):477-89.
    View in: PubMed
    Score: 0.079
  6. Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Sep; 62(4):631-46.
    View in: PubMed
    Score: 0.077
  7. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010 Feb 10; 28(5):780-7.
    View in: PubMed
    Score: 0.022
  8. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol. 2009 Sep 10; 27(26):4413-21.
    View in: PubMed
    Score: 0.022
  9. Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol. 2008 Dec; 63(1):65-74.
    View in: PubMed
    Score: 0.020
  10. Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs. 2008 Jan; 19(1):77-84.
    View in: PubMed
    Score: 0.019
  11. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 15; 12(18):5471-80.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)